Americas Cancer Immunotherapy Market Research Report, By Cancer (Prostate, Colorectal, Head & Neck Cancer), Therapeutics (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Vaccines), End Users (Hospitals, Academic Institutes) - Forecast till 2027
ID: MRFR/Pharma/0149-HCR | February 2021 | Region: Americas | 90 pages
Americas Cancer Immunotherapy Market Scenario:
The Americas cancer immunotherapy market is expected to grow at an approximate CAGR of 10.1% during the forecast period.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Figure 1:- Americas cancer immunotherapy market share, by region 
Sources: WHO, annual reports, press release, white paper, and company presentations
Segmentation
The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users.
On the basis of the cancer, the Americas cancer immunotherapy market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.
On the basis of the therapeutics, the Americas cancer immunotherapy market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others. The monoclonal antibodies segment is sub segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, chemolabeled antibodies, bispecific monoclonal antibodies, and others. The naked monoclonal antibodies segment, by monoclonal antibody segment, is father segmented into alemtuzumab, trastuzumab, and others. The immune checkpoint inhibitors segment is sub segmented into PD-1 inhibitors, PD-L1 inhibitors, and others. The PD-1 inhibitors segment, by immune checkpoint inhibitors, is sub segmented into pembrolizumab, nivolumab, and others. The PD-L1 inhibitors segment, by immune checkpoint inhibitors, is further segmented into atezolizumab, avelumab, and others. The non-specific cancer immunotherapies and adjuvants segment is sub segmented into cytokines, interleukins, and others.
On the basis of the end users, the Americas cancer immunotherapy market is segmented as hospitals & clinics, academic institutes, research organization, and others.
Regional Analysis
On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market share for the Americas cancer immunotherapy market due the presence of the U.S. within the region. This large share is also attributed due to the technologically advanced healthcare market in the region which is followed by high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure. Moreover, growing biotechnology, healthcare and life sciences sector within the region fuels the market growth regionally. The total number of the biotechnology industries in the U.S. increased from 2,763 in 2014 and reached 2,772 in 2015. Additionally, the abundance of state of the art laboratories in the U.S. is also facilitating the cancer immunotherapy market growth.
On the other hand, Latin America is the fastest growing region due to the presence of the developing economies within the region, rising healthcare expenditure and huge patient population.
Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation
Key players for the Americas cancer immunotherapy market
Some of the major player in the Americas cancer immunotherapy market are Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Therapeutics Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. The Americas Cancer Immunotherapy Market, by Cancer
6.1 Introduction
6.2 Lung Cancer
Market Estimates & Forecast, 2020-2027
6.3 Prostate Cancer
Market Estimates & Forecast, 2020-2027
6.4 Colorectal Cancer
Market Estimates & Forecast, 2020-2027
6.5 Head & Neck Cancer
Market Estimates & Forecast, 2020-2027
6.6 Others
Chapter 7. The Americas Cancer Immunotherapy Market, by Therapeutics
7.1 Introduction
7.2 Monoclonal Antibodies
Market Estimates & Forecast, 2020-2027
7.2.1 Naked Monoclonal Antibodies
7.2.1.1 Naked Monoclonal Antibodies
7.2.1.2 Alemtuzumab
7.2.1.3 Trastuzumab
7.2.1.4 Others
7.2.2 Conjugated Monoclonal Antibodies
7.2.3 Chemolabeled Antibodies
7.2.4 Bispecific Monoclonal Antibodies
7.2.5 Others
7.3 Immune Checkpoint Inhibitors
Market Estimates & Forecast, 2020-2027
7.3.1 PD-1 inhibitors
7.3.1.1 Pembrolizumab
7.3.1.2 Nivolumab
7.3.1.3 Others
7.3.2 PD-L1 inhibitors
7.3.2.1 Atezolizumab
7.3.2.2 Avelumab
7.3.2.3 Others
7.4 Vaccines
Market Estimates & Forecast, 2020-2027
7.5 Non-specific cancer immunotherapies and adjuvants
Market Estimates & Forecast, 2020-2027
7.5.1 Cytokines
7.5.2 Interleukins
7.5.3 Others
Chapter 8. The Americas Cancer Immunotherapy Market, by End Users
8.1 Introduction
8.2 Hospitals & Clinics
Market Estimates & Forecast, 2020-2027
8.3 Research Organization
Market Estimates & Forecast, 2020-2027
8.4 Retail Pharmacies
Market Estimates & Forecast, 2020-2027
8.5 Others
Chapter 9. The Americas Cancer Immunotherapy Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Amgen Inc.
11.1.1 Company Overview
11.1.2 Cancer Overview
11.1.3 Financials
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 AstraZeneca
11.2.1 Company Overview
11.2.2 Cancer Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 Company Overview
11.3.2 Cancer Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Bayer AG
11.4.1 Company Overview
11.4.2 Cancer/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Bristol-Myers Squibb Company
11.5.1 Company Overview
11.5.2 Cancer Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Eli Lilly and Company
11.6.1 Company Overview
11.6.2 Cancer Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Merck & Co., Inc.
11.7.1 Overview
11.7.2 Cancer Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Pfizer Inc.
11.8.1 Overview
11.8.2 Cancer Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Novartis AG
11.9.1 Overview
11.9.2 Cancer Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of the Americas Cancer Immunotherapy Market
Chapter 13 Appendix
LIST OF TABLES
Table 1 The Americas Cancer Immunotherapy Industry Synopsis, 2020-2027
Table 2 The Americas Cancer Immunotherapy Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 The Americas Cancer Immunotherapy Market by Region, 2020-2027, (USD Million)
Table 4 The Americas Cancer Immunotherapy Market by Cancer, 2020-2027, (USD Million)
Table 5 The Americas Cancer Immunotherapy Market by Therapeutics, 2020-2027, (USD Million)
Table 6 The Americas Cancer Immunotherapy Market by End Users, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for the Americas Cancer Immunotherapy Market
Figure 3 Market Dynamics for the Americas Cancer Immunotherapy Market
Figure 4 The Americas Cancer Immunotherapy Market Share, by Cancer 2020
Figure 5 The Americas Cancer Immunotherapy Market Share, by Therapeutics 2020
Figure 6 The Americas Cancer Immunotherapy Market Share, by End Users, 2020
Figure 7 The Americas Cancer Immunotherapy Market Share, by Region, 2020
Figure 8 The Americas Cancer Immunotherapy Market: Company Share Analysis, 2020 (%)
Figure 9 Amgen Inc.: Key Financials
Figure 10 Amgen Inc.: Segmental Revenue
Figure 11 Amgen Inc.: Geographical Revenue
Figure 12 AstraZeneca: Cancer UK Ltd: Key Financials
Figure 13 AstraZeneca: Cancer UK Ltd: Segmental Revenue
Figure 14 AstraZeneca: Cancer UK Ltd: Geographical Revenue
Figure 15 F. Hoffmann-La Roche Ltd.: Key Financials
Figure 16 F. Hoffmann-La Roche Ltd.: Segmental Revenue
Figure 17 F. Hoffmann-La Roche Ltd.: Geographical Revenue
Figure 18 Bayer AG: Key Financials
Figure 19 Bayer AG: Segmental Revenue
Figure 20 Bayer AG: Geographical Revenue
Figure 21 Bristol-Myers Squibb Company: Key Financials
Figure 22 Bristol-Myers Squibb Company: Segmental Revenue
Figure 23 Bristol-Myers Squibb Company: Geographical Revenue
Figure 24 Eli Lilly and Company: Key Financials
Figure 25 Eli Lilly and Company: Segmental Revenue
Figure 26 Eli Lilly and Company: Geographical Revenue
Figure 27 Merck & Co., Inc.: Key Financials
Figure 28 Merck & Co., Inc.: Segmental Revenue
Figure 29 Merck & Co., Inc.: Geographical Revenue
Figure 30 Pfizer Inc.: Key Financials
Figure 31 Pfizer Inc.: Segmental Revenue
Figure 32 Pfizer Inc.: Geographical Revenue
Figure 33 Novartis AG: Key Financials
Figure 34 Novartis AG: Segmental Revenue
Figure 35 Novartis AG: Geographical Revenue